Hsu Yuan-tai, who is also a member of the Biodiversity Task Force in the Executive Yuan, says that biodiversity conferences have discussed the possibility of requiring pharmaceutical manufacturers to disclose in detail the source of their product and its development process when applying for a patent, so as to ensure that the intellectual property rights of aboriginal and traditional cultures can be protected.
行政院生物多樣性工作小組成員之一的徐源泰指出，生物多樣性公約會議中，曾經討論到國際藥廠申請新藥物專利時，是否應將開發過程與來源仔細交代，以避免竊取原住民與其他文化傳統的智慧財產。